AI-generated summary
The authors report an umbrella review of 22 systematic reviews and meta-analyses on laser therapy for oral mucositis, a side effect of cancer treatment. They report that photobiomodulation was associated with reduced incidence, severity, pain and healing time, with no serious adverse events reported. The authors' endorsement as standard supportive care reflects their society's recommendation rather than a finding of the review itself.
- Studies included
- 22
- Who or what was studied
- Adult and pediatric oncology patients with oral mucositis, including those undergoing hematopoietic stem cell transplantation and head and neck chemoradiation
- Wavelengths
- 630, 670, 780, 850 nm
- Limits stated in the abstract
- The abstract does not describe the quality or heterogeneity of the included reviews, and the review's own conclusions are presented as endorsement by a professional society.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Oral mucositis (OM) is a common and debilitating side effect of cancer therapy that impairs nutrition, increases infection risk, and often disrupts oncologic treatment. Photobiomodulation therapy (PBMT) has emerged as an effective, non-invasive method for OM prevention and management. This umbrella review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines and the Joanna Briggs Institute (JBI) methodology. A comprehensive search of PubMed®/MEDLINE, Embase, Scopus, and Cochrane Library identified systematic reviews and meta-analyses on laser therapy for OM published through July 2025. The data extraction process centered on clinical outcomes, laser parameters and safety. Twenty-two reviews met the inclusion criteria. Photobiomodulation therapy significantly reduced the incidence of OM, disease severity, pain, and healing time across adult and pediatric populations. Preventive PBMT decreased the risk of severe OM (grade 3-4) by 40-80%, while therapeutic PBMT shortened ulcer duration by 4-7 days. The combination of PBMT and photodynamic therapy (PDT) enhanced mucosal healing and alleviated pain. Optimal outcomes were achieved when wavelengths of 630-670 nm (intraoral) and 780-850 nm (extraoral) were used, with fluences of 2-6 J/cm2. No serious adverse events were reported. Photobiomodulation therapy demonstrates strong efficacy and safety in the management of OM, improving quality of life and treatment continuity in oncology patients. The Polish Society for Laser Dentistry (PTSL) endorses PBMT as a standard supportive care modality, particularly in the context of hematopoietic stem cell transplantation (HSCT) and head and neck chemoradiation. Protocol adherence and parameter standardization are essential to ensure the reproducibility and clinical effectiveness of research findings.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630-670 nm, 780-850 nm
- Energy density (fluence)
- 6 J/cm2
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Laser, Oral mucositis, Photobiomodulation, Photodynamic therapy, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.